Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 15/20 | 0.65 |
| ▸ | CDK1 | P06493 | 14/20 | 0.65 |
| ▸ | CDK2 | P24941 | 13/20 | 0.65 |
| ▸ | CCND1 | P24385 | 13/20 | 0.65 |
| ▸ | CDK9 | P50750 | 11/20 | 0.65 |
| ▸ | CCNB1 | P14635 | 11/20 | 0.65 |
| ▸ | CCNT1 | O60563 | 10/20 | 0.65 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.65 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.65 |
| ▸ | CDK8 | P49336 | 4/20 | 0.65 |
| ▸ | CCNT2 | O60583 | 1/20 | 0.65 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.56 |
| ▸ | CCND3 | P30281 | 4/20 | 0.56 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.56 |
| ▸ | CCNC | P24863 | 1/20 | 0.56 |
| ▸ | CCNB2 | O95067 | 7/20 | 0.48 |
| ▸ | CCNB3 | Q8WWL7 | 7/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.48 |
| ▸ | GSK3A | P49840 | 4/20 | 0.48 |
| ▸ | CDK7 | P50613 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23682929 | 0.87 | CDK4 (0.71) | CDK4CDK1CDK2CCND1CDK9 | |
| SCHEMBL30688746 | 0.84 | CDK4 (0.68) | CDK4CDK1CDK2CCND1CDK9 | |
| SCHEMBL2446327 | 0.84 | CDK4 (0.68) | CDK4CDK1CDK2CCND1CDK9 | |
| Hydrochloric Acid SCHEMBL30688749 | 0.83 | CDK4 (0.67) | CDK4CDK1CDK2CCND1CDK9 | |
| Hydrochloric Acid SCHEMBL31632765 | 0.83 | CDK4 (0.67) | CDK4CDK1CDK2CCND1CDK9 | |
| Hydrochloric Acid SCHEMBL4015958 | 0.83 | CDK4 (0.67) | CDK4CDK1CDK2CCND1CDK9 | |
| Voruciclib SCHEMBL2446321 | 0.79 | CDK4 (1.00) | CDK4CDK1CDK2CCND1CDK9 | |
| Voruciclib SCHEMBL2446324 | 0.79 | CDK4 (1.00) | CDK4CDK1CDK2CCND1CDK9 | |
| Voruciclib SCHEMBL29366894 | 0.79 | CDK4 (1.00) | CDK4CDK1CDK2CCND1CDK9 | |
| Voruciclib SCHEMBL23436512 | 0.79 | CDK4 (1.00) | CDK4CDK1CDK2CCND1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197680-A1 | VORUCICLIB DOSING REGIMENS AND METHODS OF TREATMENT INCLUDING THE SAME | MEI PHARMA, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4319744-A1 | VORUCICLIB DOSING REGIMENS AND METHODS OF TREATMENT INCLUDING THE SAME | MEI Pharma, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197680-A1 | VORUCICLIB DOSING REGIMENS AND METHODS OF TREATMENT INCLUDING THE SAME | BCL2, MCL1, BAK1 | CDK4 239/4885CDK1 636/4885CDK2 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.